MX2019012985A - Métodos para tratar trastornos oculares con antagonistas de aplnr e inhibidores de vegf. - Google Patents

Métodos para tratar trastornos oculares con antagonistas de aplnr e inhibidores de vegf.

Info

Publication number
MX2019012985A
MX2019012985A MX2019012985A MX2019012985A MX2019012985A MX 2019012985 A MX2019012985 A MX 2019012985A MX 2019012985 A MX2019012985 A MX 2019012985A MX 2019012985 A MX2019012985 A MX 2019012985A MX 2019012985 A MX2019012985 A MX 2019012985A
Authority
MX
Mexico
Prior art keywords
methods
aplnr
eye disorders
vegf inhibitors
treating eye
Prior art date
Application number
MX2019012985A
Other languages
English (en)
Spanish (es)
Inventor
B Lobov Ivan
Cao Jingtai
Cheung Eunice
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019012985A publication Critical patent/MX2019012985A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2019012985A 2017-05-06 2018-05-04 Métodos para tratar trastornos oculares con antagonistas de aplnr e inhibidores de vegf. MX2019012985A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502621P 2017-05-06 2017-05-06
PCT/US2018/031255 WO2018208625A1 (en) 2017-05-06 2018-05-04 Methods of treating eye disorders with aplnr antagonists and vegf inhibitors

Publications (1)

Publication Number Publication Date
MX2019012985A true MX2019012985A (es) 2020-01-13

Family

ID=62555166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012985A MX2019012985A (es) 2017-05-06 2018-05-04 Métodos para tratar trastornos oculares con antagonistas de aplnr e inhibidores de vegf.

Country Status (9)

Country Link
EP (1) EP3618876A1 (ko)
JP (1) JP7161494B2 (ko)
CN (1) CN110709104A (ko)
AU (1) AU2018266324B2 (ko)
CA (1) CA3062418A1 (ko)
EA (1) EA201992630A1 (ko)
IL (1) IL270267B1 (ko)
MX (1) MX2019012985A (ko)
WO (1) WO2018208625A1 (ko)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
DE602004027798D1 (de) * 2003-03-12 2010-08-05 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
ES2406764T3 (es) 2006-06-16 2013-06-10 Regeneron Pharmaceuticals, Inc. Formulaciones que comprenden antagonistas de VEGF para administración intravítrea
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2013012855A1 (en) * 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EA033387B1 (ru) 2012-01-23 2019-10-31 Regeneron Pharma СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
US9593153B2 (en) 2012-04-11 2017-03-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Modified apelin polypeptides
JP5775851B2 (ja) 2012-06-27 2015-09-09 東京エレクトロン株式会社 塗布装置および塗布液充填方法
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EA201591700A1 (ru) * 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Гибридные белки апелина и их применение
KR20160086942A (ko) 2013-11-20 2016-07-20 리제너론 파아마슈티컬스, 인크. Ａｐｌｎｒ 조절물질 및 이들의 용도
AU2015233370A1 (en) 2014-03-20 2016-09-22 Centre National De La Recherche Scientifique (Cnrs) Use of compounds inhibiting Apelin / APJ / GP130 signaling for treating cancer
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
BR112018005737A2 (pt) * 2015-09-23 2018-10-09 Genentech Inc anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína

Also Published As

Publication number Publication date
KR20200004366A (ko) 2020-01-13
EA201992630A1 (ru) 2020-04-29
IL270267B1 (en) 2024-02-01
JP7161494B2 (ja) 2022-10-26
EP3618876A1 (en) 2020-03-11
JP2020518641A (ja) 2020-06-25
AU2018266324B2 (en) 2024-02-01
IL270267A (ko) 2019-12-31
CN110709104A (zh) 2020-01-17
CA3062418A1 (en) 2018-11-15
WO2018208625A1 (en) 2018-11-15
AU2018266324A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
SG10201807625PA (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
WO2018191548A3 (en) Complement factor d antagonist antibodies and conjugates thereof
MX2021002180A (es) Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX355042B (es) Metodos para aumentar adipositos termogenicos.
MY169165A (en) Anti-pdgfr-beta antibodies and uses thereof
MX2021007184A (es) Formas cristalinas del derivado de 4-pirimidinsulfamida aprocitentan.
MX2011012691A (es) Combinacion de un antagonista de tnf-alfa y un antagonista de vegf para utilizarse en el tratamiento o en la prevencion de enfermedades de los ojos.
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
PH12020551786A1 (en) Combination treatment for eye fibrosis and/or angiogenesis
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
PH12017500461A1 (en) Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
WO2018102670A3 (en) Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down
MX2016010852A (es) Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso.
MX2018010546A (es) Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
WO2017140684A3 (en) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX2019012985A (es) Métodos para tratar trastornos oculares con antagonistas de aplnr e inhibidores de vegf.